Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius

Positive Opinion, Stock Price Movement, and Executive Appointments - Research
 Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer

PR Newswire

NEW YORK, November 28, 2013

NEW YORK, November 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Sirona Dental Systems, Inc. (NASDAQ: SIRO),
Centene Corp. (NYSE: CNC), Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS),
and PerkinElmer, Inc. (NYSE: PKI). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report

On November 22, 2013, Celgene International Sàrl, a wholly-owned subsidiary of
Celgene Corporation (Celgene), announced that the European Medicines Agency's
(EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
positive opinion for ABRAXANE (paclitaxel formulated as albumin bound
nanoparticles, or nab-paclitaxel) in combination with gemcitabine for
first-line treatment of adult patients with metastatic adenocarcinoma of the
pancreas. According to Celgene, it expects the European Commission, which
generally follows the recommendation of the CHMP, to make the final decision
within two to three months. Alan Colowick, MD, President of Celgene Europe,
the Middle East and Africa (EMEA), said, "The positive CHMP opinion on
ABRAXANE with gemcitabine for metastatic pancreatic cancer is a significant
step toward bringing the first new treatment option in many years to people
diagnosed with this deadly disease, which has seen multiple clinical trial
failures over the years. Following a positive decision by the European
Commission within the next few months, we hope to begin the important work of
helping physicians and patients gain access to ABRAXANE plus gemcitabine,
which has demonstrated statistically significant and clinically meaningful
improvements in overall survival compared to gemcitabine alone, as reported
recently in the New England Journal of Medicine." The Full Research Report on
Celgene Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7f47_CELG

--

Sirona Dental Systems, Inc. Research Report

On November 25, 2013, Sirona Dental Systems, Inc.'s (Sirona) stock declined
4.12%, ending the day at $67.30. Over the previous three trading sessions,
shares of Sirona declined 7.25% compared to the Nasdaq Composite which gained
1.87% during the same period. The Full Research Report on Sirona Dental
Systems, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/08e7_SIRO

--

Centene Corp. Research Report

On November 25, 2013, Centene Corp.'s (Centene) stock rose 1.54%, ending the
day at $59.43. Over the previous three trading sessions, shares of Centene
rose 3.66% compared to the S&P 500 which gained 1.19% during the same period.
The Full Research Report on Centene Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/e85d_CNC

--

Fresenius Medical Care AG & Co. (ADR) Research Report

On November 25, 2013, Reuters reported that the shares of Fresenius Medical
Care AG & Co. (ADR) (Fresenius Medical Care) rose after a statement by a U.S.
healthcare agency, which informed of its intention to phase in reimbursement
cuts rather than introduce them in one hit in 2014. Reuters further reported
that Medicare, the U.S. government healthcare program for elderly and disabled
people, will spread a 9.4% cut, initially proposed to take effect in 2014,
over the next three to four years. The Reuters report also informed that
Medicare reimburses Fresenius Medical Care and other dialysis providers for
the cost of treating kidney patients covered by the Medicare program.
Commenting on the phased-in cuts, Reuters reported that each year, the cuts
will be no worse than routine annual mark-ups to adjust for inflation, making
Medicare payments remain flat at worst, for at least the next two years. The
Full Research Report on Fresenius Medical Care AG & Co. (ADR) - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/dfd9_FMS

--

PerkinElmer, Inc. Research Report

On November 21, 2013, PerkinElmer, Inc. (PerkinElmer) announced the
appointment of Jon DiVincenzo as President, Environmental Health and Senior
Vice President of PerkinElmer, effective December 2, 2013. The Company
reported that in his new role, DiVincenzo will have overall leadership
responsibility for the Company's Environmental Health business. Commenting on
the appointment, Robert F. Friel, Chairman and CEO, said, "We are delighted to
welcome Jon to PerkinElmer, further expanding the capabilities of our
leadership team. Jon's deep market knowledge and strong track record of
building and growing successful global businesses will enable him to play a
pivotal role in helping PerkinElmer accelerate growth and innovation."
PerkinElmer further added that Maurice "Dusty" Tenney, who has led the
Environmental Health business for four years, will transition to a newly
created position overseeing global operations and customer logistics for the
Corporation. The Full Research Report on PerkinElmer, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2016_PKI

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.